Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
Kaiser Permanente
University of Pennsylvania
Duke University
Ulsan University Hospital
University of Colorado, Denver
Unity Health Toronto
City of Hope Medical Center
Colorado State University
Orano Med LLC
Eli Lilly and Company
Novartis
Pfizer
Var2 Pharmaceuticals
Universidad Complutense de Madrid
Dokuz Eylul University
University of Salamanca
AC Camargo Cancer Center
City of Hope Medical Center
NantCell, Inc.
Vejle Hospital
City of Hope Medical Center
AstraZeneca
Tempus AI
UNC Lineberger Comprehensive Cancer Center
Eli Lilly and Company
Virginia Commonwealth University
University of Calgary
New Mexico Cancer Research Alliance
Arab American University (Palestine)
A2 Biotherapeutics Inc.
Centre Hospitalier de Valence
Eli Lilly and Company
GONGCHU Biotechnology Co., Ltd
Palleon Pharmaceuticals, Inc.
Jonsson Comprehensive Cancer Center
Centre for Research and Technology Hellas
Novita Pharmaceuticals, Inc.
Wake Forest University Health Sciences
Eli Lilly and Company
ModeX Therapeutics, An OPKO Health Company
University of Alabama at Birmingham
Columbia University
University of Arizona
Memorial Sloan Kettering Cancer Center
Institut du Cancer de Montpellier - Val d'Aurelle
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Stanford University